Eleanor B. Schron
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Eleanor B. Schron has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
David S. Paeth
University of Washington Seattle, Washington USA
1 shared publicationJean A. Cross
University of Washington Seattle, Washington USA
1 shared publicationJonathan Steinberg
University of Washington Seattle, Washington USA
1 shared publicationLouise S. Jenkins
From the Division of Epidemiology and Clinical Applications, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD;1 and Organizational Systems and Adult Health, School of Nursing, University of Maryland‐Baltimore, Baltimore, MD2
1 shared publication- Louise S. Jenkins
University of Maryland, School of Nursing, Suite 311, 655 West Lombard Street, Baltimore, MD 21201, USA
1 shared publication - Maria Mori Brooks
University of Pittsburgh
1 shared publication
Latest Publications
- 1 March 2005
- Published by Wiley in The American Journal of Geriatric Cardiology
- Vol. 14 (2) , 87-90
Quality of Life in Older Patients With Atrial Fibrillation
This review summarizes what is known about quality of life (QOL) in older patients with atrial fibrillation (AF). The studies reviewed in this paper represent an increasingly broad repertoire of therapies for the treatment of AF and suggest that QOL in older patients does improve with treatment. The most dramatic improvements in QOL are noted in patients who are highly symptomatic and have poorer QOL at baseline. The data from studies where ablation and pacing therapy is used for treatment in patients with refractory AF vividly demonstrate this statement. There is also evidence of improvement in QOL in those with less severe symptoms, though it is extremely challenging to measure improvements in older patients who are asymptomatic (e.g., silent AF) or mildly symptomatic. Recommendations about new knowledge needed to optimize outcomes, particularly QOL, in patients with AF are based on these findings and the gaps in existing knowledge.
- 1 March 2005
- Published by Wiley in The American Journal of Geriatric Cardiology
- Vol. 14 (2) , 87-90
Quality of Life in Older Patients With Atrial Fibrillation
This review summarizes what is known about quality of life (QOL) in older patients with atrial fibrillation (AF). The studies reviewed in this paper represent an increasingly broad repertoire of therapies for the treatment of AF and suggest that QOL in older patients does improve with treatment. The most dramatic improvements in QOL are noted in patients who are highly symptomatic and have poorer QOL at baseline. The data from studies where ablation and pacing therapy is used for treatment in patients with refractory AF vividly demonstrate this statement. There is also evidence of improvement in QOL in those with less severe symptoms, though it is extremely challenging to measure improvements in older patients who are asymptomatic (e.g., silent AF) or mildly symptomatic. Recommendations about new knowledge needed to optimize outcomes, particularly QOL, in patients with AF are based on these findings and the gaps in existing knowledge.
- 1 November 2003
- Published by Wolters Kluwer Health in Journal of Cardiovascular Nursing
- Vol. 18 (5) , 337-342
Implantable Devices Benefit Patients With Cardiovascular Diseases
Although major advances have been made in the prevention, diagnosis, and treatment of cardiovascular diseases, the prevalence of these diseases in the US population is almost 62 million, with almost 8 million having had a myocardial infarction and nearly 5 million with a diagnosis of heart failure. Increasingly implantable devices have been used to decrease mortality and morbidity in patients with coronary heart disease. The dramatic reduction in mortality reported in the recent clinical trial of implantable cardioverter defibrillators in MADIT II (Multicenter Automatic Defibrillator Trial II) and decrease in hospitalizations, improved exercise tolerance, and better quality of life with cardiovascular resynchronization therapy reported in MIRACLE (Multicenter InSync Randomized Clinical Evaluation) led the American Heart Association to name treatment with implantable devices as one of the top 10 research advances for 2002. This article reviews the pathophysiology of cardiac dysrhythmia in the context of either heart failure or low ejection fraction, standard medical therapy, results of important clinical trials of implantable cardioverter-defibrillator and offers suggestions for future directions.
- 1 November 2003
- Published by Wolters Kluwer Health in Journal of Cardiovascular Nursing
- Vol. 18 (5) , 337-342
Implantable Devices Benefit Patients With Cardiovascular Diseases
Although major advances have been made in the prevention, diagnosis, and treatment of cardiovascular diseases, the prevalence of these diseases in the US population is almost 62 million, with almost 8 million having had a myocardial infarction and nearly 5 million with a diagnosis of heart failure. Increasingly implantable devices have been used to decrease mortality and morbidity in patients with coronary heart disease. The dramatic reduction in mortality reported in the recent clinical trial of implantable cardioverter defibrillators in MADIT II (Multicenter Automatic Defibrillator Trial II) and decrease in hospitalizations, improved exercise tolerance, and better quality of life with cardiovascular resynchronization therapy reported in MIRACLE (Multicenter InSync Randomized Clinical Evaluation) led the American Heart Association to name treatment with implantable devices as one of the top 10 research advances for 2002. This article reviews the pathophysiology of cardiac dysrhythmia in the context of either heart failure or low ejection fraction, standard medical therapy, results of important clinical trials of implantable cardioverter-defibrillator and offers suggestions for future directions.
- 1 June 1995
- Published by Elsevier in Controlled Clinical Trials
- Vol. 16 (3) , 131-132
P104 Quality of life data collected before and after randomization
- 1 June 1995
- Published by Elsevier in Controlled Clinical Trials
- Vol. 16 (3) , 131-132
P104 Quality of life data collected before and after randomization